Article Sidebar
Views pdf: 64
ASSESSING TREATMENT RESULTS FOLLOWING RECOMMENDATIONS OF THE VIETNAM NATIONAL HEART ASSOCIATION IN 2022 IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AFTER 6 MONTHS OF STARTING TREATMENT AT TRIEU AN HOSPITAL IN 2023-2024
Main Article Content
Abstract
Background: In Vietnam, it is estimated that about 320,000 to 1.6 million people suffer from heart failure; accounting for 1-1.5% of the population. Heart failure with reduced ejection fraction accounts for more than 50% of heart failure cases. Objective: Assessing treatment results following recommendations of the Vietnam National Heart Association in 2022 in patients with heart failure with reduced ejection fraction after 6 months of starting treatment at Trieu An Hospital in 2023-2024. Materials and methods: Cross-sectional descriptive study on 100 patients with heart failure with reduced ejection fraction treated at the Department of Cardiology and Cardiology Outpatient Clinic of Trieu An Hospital from June 2023 to April 2024. Results: After 6 months of starting treatment, 48.0% of patients improved in the NYHA Classification of Heart Failure; The proportion of patients achieving the target heart rate (≤70 beats/minute) increased from 25.0% to 40.0% (p <0.05). 60.0% of patients improved their ejection fraction. There were no deaths during the follow-up period. 14.0% of patients were re-hospitalized within 6 months due to cardiovascular causes. Conclusion: There was an improvement in the NYHA Classification of Heart Failure and ejection fraction in patients with heart failure with reduced ejection fraction treated according to the recommendations of the Vietnam National Heart Association in 2022 at Trieu An Hospital. There were no deaths
Article Details
Keywords
heart failure with reduced ejection fraction, recommendations of the Vietnam National Heart Association, treatment
References
2. Huỳnh Đông Nhựt (2019), Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và đánh giá hiệu quả điều trị của thuốc chẹn beta trên bệnh nhân suy tim mạn có phân suất tống máu giảm tại Bệnh viện Tim mạch An Giang, Luận văn Chuyên khoa cấp 2, Trường Đại học Y dược Cần Thơ.
3. Phan Đình Phong (2024), “Thực trạng sử dụng các nhóm thuốc nền tảng trong điều trị suy tim mạn tính có phân suất tống máu giảm tại Khoa Khám bệnh - Bệnh viện Bạch Mai”, Tạp Chí Y học Việt Nam, 535(1B). tr. 238-243.
4. Nguyễn Duy Toàn (2017), Nghiên cứu rối loạn nhịp tim và rối loạn dẫn truyền trong thất ở bệnh nhân suy tim mạn tính có giảm phân số tống máu thất trái, Luận án tiến sĩ y học, Học viện Quân y.
5. Phạm Nguyễn Vinh, Phạm Mạnh Hùng, Đặng Vạn Phước và cộng sự (2022), “Khuyến cáo của Hội Tim Mạch Quốc Gia Việt Nam về chẩn đoán và điều trị suy tim cấp và suy tim mạn”.
6. Abdin A., Bauersachs J., Soltani S., et al. (2023), “A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction”, ESC Heart Failure, 10, pp. 24-31.
7. Cleland J. G. F., Bunting K. V. , Flather M. D., et al. (2018), “Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials”, European Heart Journal, 39(1), pp. 26-35.
8. Diamant M.J., Virani S.A., MacKenzie W.J., et al. (2019), “Medical therapy doses at hospital discharge in patients with existing and de novo heart failure”, ESC Heart Fail, 6(4), pp. 774-783.
9. Greene S.J., Triana T.S., Ionescu-Ittu R., et al. (2020), “In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United State”, JACC Heart Fail, 8(11), pp. 943-953.
10. Harrington J., Sun J.L., Fonarow G.C., et al. (2023), “Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction”, J Am Heart Assoc, 12, pp. e028820.